Avraham Pharmaceuticals Company
Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease, supporting the development of its lead product candidate, ladostigil.
Technology:
Biotechnology, Health Care, Pharmaceutical
Industry:
Preventive Medicine
Headquarters:
Yavneh, Israel
Founded Date:
2010
Employees Number:
1-10
Funding Status:
N/A
Register and Claim Ownership